home / stock / lgnd / lgnd quote
Last: | $84.79 |
---|---|
Change Percent: | 0.0% |
Open: | $84.85 |
Close: | $84.79 |
High: | $85.61 |
Low: | $84.04 |
Volume: | 115,722 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$84.79 | $84.85 | $84.79 | $85.61 | $84.04 | 115,722 | 07-02-2024 |
$84.85 | $83.76 | $84.85 | $85.72 | $82.98 | 145,692 | 07-01-2024 |
$84.26 | $82.72 | $84.26 | $84.33 | $81.86 | 328,417 | 06-28-2024 |
$82.33 | $78.45 | $82.33 | $82.88 | $78.2 | 115,275 | 06-27-2024 |
$77.82 | $78.45 | $77.82 | $79.025 | $77.53 | 83,716 | 06-26-2024 |
$78.9 | $80 | $78.9 | $80.3 | $78.44 | 83,612 | 06-25-2024 |
$79.96 | $79.81 | $79.96 | $81.2 | $79.81 | 72,484 | 06-24-2024 |
$79.39 | $79.92 | $79.39 | $81.12 | $79.07 | 182,564 | 06-21-2024 |
$79.81 | $79.9 | $79.81 | $81.0146 | $79.33 | 69,605 | 06-20-2024 |
$80.54 | $80.27 | $80.54 | $81.2916 | $79.5 | 92,292 | 06-19-2024 |
$80.54 | $80.27 | $80.54 | $81.2916 | $79.5 | 92,292 | 06-18-2024 |
$80.64 | $80 | $80.64 | $80.75 | $77.58 | 94,894 | 06-17-2024 |
$80.06 | $81.04 | $80.06 | $81.23 | $78.81 | 85,117 | 06-14-2024 |
$81.34 | $80.17 | $81.34 | $81.52 | $78.91 | 71,823 | 06-13-2024 |
$80.15 | $80.59 | $80.15 | $81.89 | $80.15 | 80,608 | 06-12-2024 |
$80.1 | $78.85 | $80.1 | $80.42 | $77.51 | 114,170 | 06-11-2024 |
$79.53 | $80.61 | $79.53 | $80.61 | $77.425 | 136,834 | 06-10-2024 |
$81.36 | $81.38 | $81.36 | $82.2 | $79.69 | 142,479 | 06-07-2024 |
$82.37 | $83.41 | $82.37 | $83.41 | $81.485 | 96,534 | 06-06-2024 |
$83.6 | $81.22 | $83.6 | $84.15 | $80.31 | 85,814 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced it has reached a cooperation agreemen...
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...